Author

K. Kousoulas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Dahai· 1 shared B. Breitenstein· 1 shared F. Musarrat· 1 shared G. S. Tan· 1 shared H. Dulin· 1 shared I. K. Uche· 1 shared M. McGee· 1 shared P. Rider· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Dahai

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Herpes Simplex Virus Type-1-derived influenza vaccine induces balanced adaptive immune responses and protects mice from lethal influenza virus challenge.

P. Rider, H. Dulin, I. K. Uche, M. McGee, B. Breitenstein, G. S. Tan, W. Huang, K. Kousoulas, R. Hai

bioRxiv · Aug 5, 2021Microbiology

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections

F. Musarrat, V. Chouljenko, R. Nabi, A. Dahai, S. Jois, K. Kousoulas

This paper shows that nelfinavir mesylate inhibits SARS-CoV-2 S glycoprotein-mediated cell fusion, suggesting its potential as an antiviral against COVID-19.

bioRxiv · Apr 24, 2020Microbiology